Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Boston's HiFiBiO Raises $37.5 Million from China Investors

publication date: May 16, 2018

HiFiBiO Therapeutics, a Boston company developing therapeutic immune modulators, closed a $37.5 million Series B financing led by two China investors, Sequoia Capital and Lyfe Capital. According to HiFiBiO, it discovers molecules based on single-B-cell screening and analysis. The company said the funding would transform HiFiBiO into a more mature biopharmaceutical company, with a stronger global presence and rich pipeline of novel antibodies for cancer and autoimmune disorders. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital